In Ireland, Nuritas announced a collaboration with BASF Human Nutrition that grants BASF an exclusive, royalty-based license to commercialize one of Nuritas’s existing peptides across a number of applications. This collaboration will also provide BASF on-demand discovery of new peptides to further expand its portfolio of essential nutrients for health benefits, for example anti-inflammatory activities.
Peptides are biologically occurring short chains of amino acids that act as potent signaling molecules in the body. This effort will target, discover and commercialize peptide networks that are natural, food-derived, patented and of significant benefit to the health of consumers.
To drive this on-demand discovery of new peptides, Nuritas will deploy its unique technology platform that uses artificial intelligence and DNA analysis to predict, unlock and validate highly efficacious peptides, exclusively from natural sources. BASF will use its scientific know-how and global reach for the scale-up, formulation and commercialization of new bioactive peptide ingredients.